Jounce Therapeutics Reports First Quarter 2021 Financial Results
May 04, 2021 06:30 ET
|
Jounce Therapeutics, Inc.
- Enrollment on track in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the biomarker selected Phase 2 SELECT trial of Vopratelimab in combination with Pimivalimab - - Ended the...
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
April 28, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
February 25, 2021 06:30 ET
|
Jounce Therapeutics, Inc.
- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 - - Ended 2020 with $213.2 million in...
Jounce Therapeutics Reports Third Quarter 2020 Financial Results
November 06, 2020 07:00 ET
|
Jounce Therapeutics, Inc.
-On track to begin enrollment in the Phase 1 trial for JTX-8064 by year-end 2020- -Established exclusive license agreement with Gilead for JTX-1811- -Initiated the Phase 2 SELECT...
Jounce Therapeutics Announces Update on Vopratelimab Program
November 02, 2020 07:00 ET
|
Jounce Therapeutics, Inc.
- No further enrollment in EMERGE trial of vopratelimab in combination with ipilimumab based on interim analysis- - First patient dosed in SELECT trial of vopratelimab in combination with JTX-4014 in...
Jounce Therapeutics to Participate in Upcoming Virtual Investor Conferences in September
September 02, 2020 16:01 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
August 07, 2020 06:30 ET
|
Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting
June 22, 2020 09:00 ET
|
Jounce Therapeutics, Inc.
- Preclinical data supports the development of JTX-1811, targeting CCR8, as a novel immunotherapy for the selective depletion of immunosuppressive tumor-infiltrating T-regulatory cells - -...
Jounce Therapeutics to Present First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at the American Association for Cancer Research Virtual Annual Meeting
May 15, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports First Quarter 2020 Financial Results
May 06, 2020 06:30 ET
|
Jounce Therapeutics, Inc.
– Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 – – Announcing CCR8 as JTX-1811 target; new preclinical data to be presented at the AACR 2020 June virtual meeting – –...